Tag: ponatinib

CML patients in England win access to Incyte’s Iclusig

by Selina McKee | May 2, 2017 | News | 0

Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine kinase inhibitor (TKI) therapies are on the brink of getting full-access to Incyte’s Iclusig on the NHS following a nod from NICE.

Takeda completes ARIAD buy

by Selina McKee | Feb 17, 2017 | News | 0

Takeda has now completion of its $5.2 billion acquisition of ARIAD Pharmaceuticals, in a deal that significantly boosts the Japanese drugmaer’s global cancer portfolio.